Dabrafenib Mesylate
The mesylate salt form of dabrafenib, a BRAF V600E/K inhibitor used for treating metastatic melanoma, NSCLC, and anaplastic thyroid cancer with BRAF mutations. The mesylate salt improves the compound's pharmaceutical properties.
Peso molecular
615,7000 g/mol
TPSA
210,00 Ų
Áreas terapéuticas
Mecanismo de acción
Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.
Estructura 2D
Cite this structure
Embed this structure
SMILES
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
InChI
InChI=1S/C23H20F3N5O2S2.CH4O3S/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25;1-5(2,3)4/h4-11,31H,1-3H3,(H2,27,28,29);1H3,(H,2,3,4)
Molecular Formula
C24H24F3N5O5S3
HBD / HBA
3 / 14
Enlaces Rotables
6
Átomos Pesados
40
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
The mesylate salt form of dabrafenib, a BRAF V600E/K inhibitor used for treating metastatic melanoma, NSCLC, and anaplastic thyroid cancer with BRAF mutations. The mesylate salt improves the compound's pharmaceutical properties.
Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.
Yes, Dabrafenib Mesylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2105729. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 44516822. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="dabrafenib-mesylate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/dabrafenib-mesylate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/dabrafenib-mesylate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/dabrafenib-mesylate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="dabrafenib-mesylate"></drugfyi-drug>